Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1077-1083

  Lane, Steven ^a   Gill, Devinder ^b   McMillan, Nigel A J ^c   Saunders, Nicholas ^c   Murphy, Rachel ^c   Spurr, Terrence ^c   Keane, Colm ^b   Fan, Helen Mar ^b   Mollee, Peter ^b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acute myeloid leukemia; Cytosine arabinoside; Elderly; Histone deacetylase inhibitor; Valproic acid

Indexed keywords

CYTARABINE; HISTONE H3; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOSTASIS; CYTOTOXICITY; DRUG BLOOD LEVEL; FEMALE; GERIATRIC PATIENT; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CYTARABINE; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PRIMARY CELL CULTURE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VALPROIC ACID;

EID: 84861359248     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.642302     Document Type: Article

References (34)

1. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute; 2004.
2. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481-3485.
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163. (Pubitemid 41130866)
4. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years:results from AMLSG trial AML HD98-B. Blood 2006;108:3280-3288.
5. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51. (Pubitemid 43054973)
6. Tang R, Faussat AM, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004;18:1246-1251. (Pubitemid 39023135)
7. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84. (Pubitemid 40215841)
8. Pilatrino C, Cilloni D, Messa E, et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005;104:101-109. (Pubitemid 40847757)
9. Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106:112-119. (Pubitemid 43032555)
10. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004;104:1266-1269. (Pubitemid 39166498)
11. Bellos F, Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologi 2008;31:629-633.
12. Siitonen T, Koistinen P, Savolainen ER. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells. Leuk Res 2005;29:1335-1342. (Pubitemid 41297646)
13. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108:1174-1182. (Pubitemid 44232012)
14. Maggio SC, Rosato RR, Kramer LB, et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fl udarabine to induce apoptosis in human leukemia cells. Cancer Res 2004;64:2590-2600. (Pubitemid 38523917)
15. ten Cate B, Samplonius DF, Bijma T, et al. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicininduced apoptosis in acute myeloid leukemic cells. Leukemia 2007;21:248-252. (Pubitemid 46158116)
16. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-3279.
17. Spriggs D, Griffin J, Wisch J, et al. Clinical pharmacology of lowdose cytosine arabinoside. Blood 1985;65:1087-1089. (Pubitemid 15121929)
18. Grimwade D, Moorman A, Hills R, et al. Impact of karyotype on treatment outcome in acute myeloid leukemia. Ann Hematol 2004;83(Suppl. 1):S45-S48.
19. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-3674.
20. Common Toxicity Criteria, Version 2.0. [Internet] National Cancer Institute. 1998. - [cited 2011 Dec 5] Available from: http://ctep.cancer. gov/protocolDevelopment/electronic-applications/ctc.htm
21. Xie C, Edwards H, Xu X, et al. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 2010;16:5499-5510.
22. Tang R, Faussat A, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid meukemia cells expressing P-gp and MRP1. Leukemia 2004;18:1246-1251. (Pubitemid 39023135)
23. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-4635. (Pubitemid 44297814)
24. Shiozawa K, Nakanishi T, Tan M, et al. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 2009;15:1698-1707.
25. Burnett A, Baccarani M, Johnson P, et al. Effectiveness of clofarabine in elderly AML patients with adverse cytogenetics unfit for intensive chemotherapy. Blood 2006;108(Suppl. 1): Abstract 1985.
26. Corsetti MT, Salvi F, Perticone S, et al. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. Leuk Res 2011;35:991-997.
27. Bug G, Ritter M, Wassmann B, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005;104:2717-2725. (Pubitemid 41798282)
28. Cimino G, Lo-Coco F, Fenu S, et al. Sequential valproic acid/ all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia. Cancer Res 2006;66:8903-8911. (Pubitemid 44449209)
29. Raffoux E, Chaibi P, Dombret H, et al. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 2005;90:986-988. (Pubitemid 41020306)
30. Khanim FL, Bradbury CA, Arrazi J, et al. Elevated FOSBexpression; a potential marker of valproate sensitivity in AML. Br J Haematol 2009;144:332-341.
31. Raffoux E, Cras A, Recher C, et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010;1:34-42.
32. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110:2302-2308. (Pubitemid 47523148)
33. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase study of the combination of 5-aza-2 ' -deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-3279.
34. Blum W, Klisovic RB, Hackanson B, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-389